ClearPoint Neuro completed the first clinical procedure with its FDA‑cleared Velocity Alpha MR High Speed Surgical Drill System on April 22, 2026, marking the first real‑world use of a device that can safely operate in an MRI suite. The 510(k) clearance authorizes the drill for trephination, incision, cutting, removal, shaping, and sawing of soft and hard tissue, bone, and biomaterials in or near a 3.0‑Tesla magnetic field, enabling neurosurgeons to perform complex procedures with greater precision.
The drill’s design delivers tactile feedback during bone access and facilitates consistent, predictable skull opening even when the bone is not fully visualized. Dr. Paul Larson, Chief Medical Officer, noted that for cases involving multiple trajectories, integration with ClearPoint’s SmartFrame platform “has the potential to reduce my procedure times by an hour or more.” The system’s reduced dimensions, increased power and torque, and lower thermal warming represent a significant evolution from the 2015 Velocity Alpha attachment series.
Strategically, the launch extends ClearPoint’s precision‑delivery platform into a new procedural area, supporting its drug‑delivery ecosystem and offering a broader range of surgical options to biopharma partners and hospitals. The partnership with adeor medical AG, the manufacturer of the drill, has been in place since at least August 2021 and positions ClearPoint as a key infrastructure provider for CNS gene and cell therapies. The first clinical use demonstrates the system’s readiness for real‑world application and may accelerate future product launches, reinforcing the company’s Fast Forward phase of growth.
Financially, ClearPoint reported Q4 2025 revenue of $10.41 million, a 20% year‑over‑year increase, and a full‑year 2025 revenue of approximately $37 million. Q1 2025 revenue rose 11% to $8.5 million, with a gross margin of 60%, but the company posted a loss of 22 cents per share, missing consensus estimates. The Q4 2025 loss of 27 cents per share also fell short of expectations. Despite these profitability challenges, single‑use device sales grew 104%, underscoring the company’s expanding product mix and the potential upside of its new offerings.
Management emphasized confidence in the company’s trajectory. Joe Burnett, President and CEO, said the 2025 fiscal year “is off to a strong start as we enter the Fast Forward phase of the company, starting with a record revenue quarter and fueled by multiple new product launches that are delivering on our promise of fast, simple and predictable procedures.” Dominic Hasbach, CEO of adeor medical AG, praised the drill’s performance, stating, “Seeing this newly developed drill achieve FDA clearance and perform well in the first clinical use is exactly the kind of outcome we work towards,” and added, “The Velocity Alpha MR high‑speed system is a product that truly reflects this experience – built by a team that knows the neurosurgical environment inside out. We deeply value our partnership with ClearPoint Neuro and are genuinely proud to play a role in contributing to further streamline the surgical workflow for their SmartFrame navigation platform.”
The milestone confirms ClearPoint’s ability to translate regulatory approvals into clinical practice, reinforcing its position as a critical infrastructure partner for advanced CNS therapies. The successful first use signals that the company’s precision‑delivery platform is ready for broader adoption, potentially accelerating the commercialization of future products and strengthening its competitive edge in the neurosurgical market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.